Ranbaxy wins FDA approval for blood pressure drug
The application for the drug was submitted by Ranbaxy, from its Ohm Laboratories manufacturing facility, at New Jersey, US. The Office of Generic Drugs, FDA, had determined the
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.